secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001558370-25-006106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3
--------------------------------------------------------------------------

- Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.
- Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.
- LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.
- Proof-of-concept data readout for LNCB74 planned in first half of 2026.
- Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/0001558370-25-006106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/nxtc-20250501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer